Advertisement

Pancreatic Adenocarcinoma Surveillance Counterpoint: Japan

  • Ken ShirabeEmail author
  • Yoshihiko Maehara
Chapter
Part of the Current Clinical Oncology book series (CCO)

Abstract

The incidence of pancreatic cancer has increased steadily over the last 4 decades. It is now the fifth leading cause of cancer death in Japan. Pancreatic cancer was responsible for the death of more than 22,000 Japanese in 2004 [1]. However, therapeutic modalities for resectable cases vary among institutions throughout the country. More than 90 % of the cancers are invasive ductal carcinomas, most of which are advanced. Series published since the year 2000 have exhibited variability in the probability of long-term survival for patients undergoing resection of pancreatic ductal adenocarcinoma. In these series, the probability of 5-year survival ranged from 12 to 32 % [2–8].

Keywords

Pancreatic carcinoma Japan Recurrent site Postoperative adjuvant chemotherapy 

References

  1. 1.
    Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic cancer registry in Japan. 20 years of experience. Pancreas. 2004;28:219–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Helm JF, Centeno BA, Coppola D, et al. Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control. 2008;15:288–94.PubMedGoogle Scholar
  3. 3.
    Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199–210.PubMedCrossRefGoogle Scholar
  4. 4.
    Takai S, Satoi S, Toyokawa H, et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single institution experience. Pancreas. 2003;26:243–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Moon HJ, An JY, Heo JS, et al. Predicting survival after surgical resection for pancreatic ductal carcinoma. Pancreas. 2006;32:37–43.PubMedCrossRefGoogle Scholar
  6. 6.
    Richter A, Niedergethmann M, Strum JW, et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003;32:271–5.Google Scholar
  7. 7.
    Schmidt CM, Powell ES, Yiannoutsos CT, et al. Pancreaticoduodenectomy: 20-year experience in 516 patients. Arch Surg. 2004;139:718–25.PubMedCrossRefGoogle Scholar
  8. 8.
    Han SS, Jang JK, Kim SW, et al. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas. 2006;32:271–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Iott MJ, Corsini MM, Miller RC. Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas. Clin J Oncol Nurs. 2008;12:599–605.PubMedCrossRefGoogle Scholar
  10. 10.
    Doi R, Imamura M, Hosotani R, et al. Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final surveillance results of a randomized multi-institutional trial. Surg Today. 2008;38:1021–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery. 2005;138:618–28.PubMedCrossRefGoogle Scholar
  12. 12.
    Iqbal N, Lovegrove RE, Tilney HS, et al. A comparison of ­pancreaticoduodenectomy with extended pancreaticoduodenectomy: a meta-analysis of 1909 patients. Eur J Surg Oncol. 2009;35: 79–86.PubMedCrossRefGoogle Scholar
  13. 13.
    Niedergethmann M, Shang E, Farag Soliman M, et al. Early and enduring nutritional and functional results of pylorus preservation vs classic Whipple procedure for pancreatic cancer. Langenbecks Arch Surg. 2006;391(3):195–202.PubMedCrossRefGoogle Scholar
  14. 14.
    Buttrini G, Stocken DD, Wente MN, et al. Influence of resection margins and treatment on survival in patients with pancreatic ­cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008;143:75–83.CrossRefGoogle Scholar
  15. 15.
    Yermilov I, Bentrem D, Sekeris E, et al. Readmissions following pancreaticoduodenectomy for pancreas cancer: a population-based appraisal. Ann Surg Oncol. 2009;16:554–61.PubMedCrossRefGoogle Scholar
  16. 16.
    Hishinuma S, Ogata Y, Tomikawa M, et al. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10:511–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. A randomized controlled trial. JAMA. 2007;297:267–77.PubMedCrossRefGoogle Scholar
  18. 18.
    Moore MJ. Pancreatic cancer: what the oncologist can offer palliation. Can J Gastroenterol. 2002;16:121–4.PubMedGoogle Scholar
  19. 19.
    Ueno H, Kosuge T. Adjuvant treatments for resectable pancreatic cancer. J Hepatobiliary Pancreat Surg. 2008;15:468–72.PubMedCrossRefGoogle Scholar
  20. 20.
    Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations of the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49: 480–509.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press 2013

Authors and Affiliations

  1. 1.Department of Surgery and Science, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations